California law mandates Rho(D) testing for all pregnant women since 1970.
Reporting of Rho(D) Hemolytic Disease of the Newborn (HDN) to the State Department of Public Health is required.
Accurate morbidity and mortality data for Rho(D) HDN in California are crucial for assessing intervention effectiveness.
Purpose of the Study:
To analyze the incidence and mortality trends of Rho(D) Hemolytic Disease of the Newborn in California.
To evaluate the impact of public health interventions and the use of anti-Rho(D) immune globulin.
To provide accurate epidemiological data on Rho(D) HDN.
Main Methods:
Analysis of mandatory reporting data for Rho(D) HDN cases and outcomes in California.
Review of historical data since 1950 to identify trends.
Comparison of recent data with literature and other state health departments.
Main Results:
A precipitous fall in Rho(D) HDN deaths and cases observed in the past two years.
Significant decrease in HDN incidence and mortality following the implementation of reporting and widespread anti-Rho(D) immune globulin use.
California's reporting law provides accurate, comprehensive data on Rho(D) HDN trends.
Conclusions:
Mandatory testing, routine anti-Rho(D) immune globulin administration, early treatment, and reduced family size have dramatically decreased Rho(D) HDN.
California's public health initiatives have led to accurate tracking and a significant reduction in Rho(D) HDN morbidity and mortality.
The study highlights the success of a comprehensive public health approach in managing and preventing Rho(D) Hemolytic Disease of the Newborn.